T
TauRx Pharmaceuticals
Developing tau aggregation inhibitors for neurodegenerative diseases
About TauRx Pharmaceuticals
TauRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company was co-founded in 2002 as a spin-out from the University of Aberdeen by Professor Claude Wischik and the late K. M. Seng. Professor Wischik's research, which began in 1988 at Cambridge University, identified that the aggregation of tau protein into tangles within nerve cells is a critical factor in the progression of dementia.
Read full description
The company's primary focus is on developing Tau Aggregation Inhibitors (TAIs), which are designed to dissolve existing tau protein tangles and prevent new ones from forming. Their lead product candidate is hydromethylthionine mesylate (HMTM), previously known as LMTX, a second-generation TAI administered orally. HMTM targets the underlying pathology of Alzheimer's and has been evaluated in several clinical trials, including the recent Phase 3 LUCIDITY study, which has shown potential in slowing cognitive decline and brain atrophy. The company is currently seeking regulatory approval for HMTM in the United Kingdom.
Headquartered in Singapore with primary research facilities in Aberdeen, Scotland, TauRx operates through extensive research and development, clinical trials, and aims for the eventual commercialization of its products. Its business model includes forming strategic partnerships, such as a joint venture with Genting Group, to aid in clinical development and healthcare delivery. The company is also involved in creating diagnostic tools to support early diagnosis and treatment monitoring for dementia.
At a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Aberdeen, United Kingdom
- Employees
- 78
- Open positions
- None listed
- Dealroom signal
- 38.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Alzheimers Disease, Spinout, Rumoured $1B, Biotech and Pharma, uk is8 life sciences, UKSU, Hard Tech, proteomics
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2022 | $119M | $476M | Undisclosed | ↗ |
| GROWTH EQUITY VCOther financing | Mar 2022 | $0 | — | Arcane Group | — |
Growth signals
Latest recorded traffic for TauRx Pharmaceuticals is 14K monthly website visits, down 6.7% over the last three months. TauRx Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Genting Singapore
Dundee Corporation
Arcane Group
Other known investors2 additional known investors
University of Aberdeen
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TauRx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TauRx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.